Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Social media is buzzing with strong opinions about the "best" place to inject GLP-1 medications — but experts say it simply doesn't matter. As long as the shot goes subcutaneously into one of the three FDA-approved sites (abdomen, thigh, or upper arm), effectiveness is the same. Clinicians should be ready to address patient misconceptions while validating individual preferences.
Social media is full of passionate takes on where to inject GLP-1 medications — some users swear by the abdomen, others say the thigh reduces nausea, and a few claim one side of the stomach works better than the other. But experts are unanimous: there's no evidence that any of the three FDA-approved subcutaneous injection sites (abdomen, thigh, or upper arm) is superior in terms of effectiveness or tolerability.
Obesity medicine physicians and physician assistants interviewed by Medscape emphasize that what matters is getting the medication under the skin — not intramuscularly — at one of the approved sites. Absorption rates are similar across all three locations. Clinicians also recommend rotating sites weekly to prevent scar tissue buildup.
Key Takeaways:
Why it matters: With GLP-1 use surging, patients are increasingly turning to social media for guidance — often encountering misinformation. Clinicians need to proactively address injection-site myths while respecting patients' personal experiences.
